ENTtoday
  • Home
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Multimedia
    • Video
    • Audio
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
    • eNewsletters
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Meningitis Vaccine Leads to Greater Reduction in Ear Infections

by Sheri J. Polley • August 1, 2007

  • Tweet
  • Email
Print-Friendly Version

Approximately 80% of children three years of age and younger are affected by otitis media, with treatment costs estimated at more than $5 billion per year. The affliction is painful for children and frustrating and costly for parents. The introduction of the heptavalent pneumococcal conjugate vaccine in 2000 caused a reduction in the number of ear infections caused by Streptococcus pneumoniae bacteria. New research shows that the effect of this vaccine on reduction of serious pediatric ear infections and the need for insertion of ventilating ear tubes may be even greater than anticipated.

You might also like:

  • Researchers Close In on Ear Infection Vaccine
  • Pediatric Ear Infections: Watchful Waiting May Be the Best Strategy
  • Surgical Indications for Pediatric Turbinate Reduction: Arguments For and Against
  • Promise for Recurrent Respiratory Papillomatosis: Pediatric otolaryngologists have high hopes for the HPV vaccine
Explore this issue:
August 2007

The Heptavalent Pneumococcal Conjugate Vaccine

S. pneumoniae is the leading cause of bacterial meningitis in the United States. It also causes other serious problems such as blood infections, pneumonia, and ear infections. Up to one-third of ear infections are believed to be caused by the S. pneumoniae bacteria.

The heptavalent pneumococcal conjugate vaccine (PCV7), which was licensed in the United States in February 2000, is marketed by Wyeth Pharmaceuticals as Prevnar. In June 2000, the Centers for Disease Control and Prevention (CDC) recommended that all children aged 23 months and younger receive the PCV7 vaccine. That same month, the American Academy of Pediatrics (AAP) issued its own recommendation that mimicked that of the CDC. Both agencies further recommended that children between 24 and 59 months of age who were determined to be at especially high risk should also be vaccinated. This includes children who have illnesses or take medications that affect the immune system or who have chronic heart or lung disease.

The vaccine is administered in four doses, given at 2, 4, 6, and 12 to 15 months of age, and can be incorporated into the scheduled administration of other childhood vaccines. Children who are allergic to any component of Prevnar should not receive the vaccine, and any child who is moderately or severely ill should wait until he or she has recovered before receiving the vaccine. A full four-dose regimen of Prevnar is 97% effective in preventing the seven strains of the pneumococcus bacterium included in the vaccine. Health officials believe that even a reduced regimen of the vaccine will provide some benefit.

According to Peter Paradiso, PhD, Vice-President of Scientific Affairs for Wyeth Vaccines, the prelicensure studies of the Prevnar vaccine conducted in California and Finland showed 25% to 40% reductions in ear tube placement, regardless of cause. He stated in a telephone interview, It was clear in children who had serious ear infections and recurrent ear infections leading to ear tubes, that there was significant reduction as a result of the vaccination.

Pages: 1 2 3 Single Page

Filed Under: Otology/Neurotology, Pediatric Issue: August 2007

You might also like:

  • Researchers Close In on Ear Infection Vaccine
  • Pediatric Ear Infections: Watchful Waiting May Be the Best Strategy
  • Surgical Indications for Pediatric Turbinate Reduction: Arguments For and Against
  • Promise for Recurrent Respiratory Papillomatosis: Pediatric otolaryngologists have high hopes for the HPV vaccine

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • How Writing Helps a Medical Resident Better Care for Patients
  • How Physicians Can Build a Network to Boost Their Career
  • How To Survive the First Year of Medical Residency
  • ACGME Revises Cap on Resident Work Hours
  • Ethical Implications of Burnout in Otolaryngology Residents
  • Popular this Week
  • Most Popular
  • Most Recent
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Counseling Patients on Safe Nasal Irrigation
    • Is There a Crisis in the Otolaryngology Match?
    • Weaning Patients Off of PPIs
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Short-and Long-Term Data Suggest Efficacy of Turbinate Ablation
    • Counseling Patients on Safe Nasal Irrigation
    • Artificial Intelligence and Machine Learning in Otolaryngology
    • Letter from the Editor: Peer Reviewing Sensational Headlines
    • Is Topical Epinephrine Safe for Hemostasis in Endoscopic Sinus Surgery?
    • Is it Safe to Kiss in Era of HPV Head and Neck Cancer ‘Epidemic’?

Polls

Is artificial intelligence an advantage for medicine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy

Visit: The Triological Society • The Laryngoscope • Triological Meeting Posters

Wiley
© 2019 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.